Magellan Health, Inc. (NASDAQ:MGLN) CEO Mostafa Kamal sold 1,154 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.00, for a total transaction of $106,168.00. Following the transaction, the chief executive officer now directly owns 1,154 shares in the company, valued at approximately $106,168. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mostafa Kamal also recently made the following trade(s):

  • On Thursday, September 28th, Mostafa Kamal sold 4,848 shares of Magellan Health stock. The shares were sold at an average price of $85.76, for a total transaction of $415,764.48.
  • On Wednesday, September 27th, Mostafa Kamal sold 19,126 shares of Magellan Health stock. The shares were sold at an average price of $85.33, for a total transaction of $1,632,021.58.
  • On Friday, September 15th, Mostafa Kamal sold 2,961 shares of Magellan Health stock. The shares were sold at an average price of $84.00, for a total transaction of $248,724.00.
  • On Wednesday, September 13th, Mostafa Kamal sold 604 shares of Magellan Health stock. The shares were sold at an average price of $83.00, for a total transaction of $50,132.00.
  • On Monday, September 11th, Mostafa Kamal sold 670 shares of Magellan Health stock. The shares were sold at an average price of $83.00, for a total transaction of $55,610.00.
  • On Friday, September 8th, Mostafa Kamal sold 6,267 shares of Magellan Health stock. The shares were sold at an average price of $81.53, for a total transaction of $510,948.51.
  • On Thursday, September 7th, Mostafa Kamal sold 2,190 shares of Magellan Health stock. The shares were sold at an average price of $81.07, for a total transaction of $177,543.30.

Magellan Health (NASDAQ:MGLN) last posted its earnings results on Wednesday, November 1st. The company reported $1.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.24. The firm had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Magellan Health had a net margin of 1.68% and a return on equity of 9.20%. The company’s revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.39 earnings per share.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/03/insider-selling-magellan-health-inc-mgln-ceo-sells-1154-shares-of-stock.html.

Several institutional investors have recently modified their holdings of MGLN. UBS Asset Management Americas Inc. lifted its stake in shares of Magellan Health by 10.4% in the first quarter. UBS Asset Management Americas Inc. now owns 19,167 shares of the company’s stock worth $1,323,000 after buying an additional 1,802 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of Magellan Health by 3.9% in the first quarter. Teachers Advisors LLC now owns 267,082 shares of the company’s stock worth $18,442,000 after buying an additional 9,928 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Magellan Health by 4.9% in the first quarter. Vanguard Group Inc. now owns 2,118,487 shares of the company’s stock worth $146,282,000 after buying an additional 98,314 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Magellan Health by 6.1% in the first quarter. Geode Capital Management LLC now owns 305,624 shares of the company’s stock worth $21,103,000 after buying an additional 17,460 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Magellan Health by 53,778.2% in the first quarter. BlackRock Inc. now owns 3,012,867 shares of the company’s stock worth $208,038,000 after buying an additional 3,007,275 shares during the last quarter. Institutional investors and hedge funds own 93.25% of the company’s stock.

A number of equities analysts have recently commented on the stock. KeyCorp reissued a “buy” rating and issued a $89.00 target price on shares of Magellan Health in a research note on Friday, September 22nd. ValuEngine raised shares of Magellan Health from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Zacks Investment Research raised shares of Magellan Health from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research note on Tuesday, July 18th. BidaskClub downgraded shares of Magellan Health from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $94.00 target price on shares of Magellan Health in a research note on Friday, October 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $83.00.

About Magellan Health

Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).

Insider Buying and Selling by Quarter for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.